Abstract:Sporadic amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease with unknown causes and few treatment options. Here we report the first multi-dimensional single-cell landscape of the peripheral blood mononuclear cell samples from seven ALS patients representing three distinct disease stages: Early, Mid and Late. Our multipronged analyses revealed the over-activation of immune cells especially in the Mid and Late ALS stages, which is characterized by the increased cytotoxic CD8+ effector cells, expanded TCR clonotypes, upregulated oxidative phosphorylation and ribosomal genes across many cell types. More importantly, the current study discovered novel genes strongly correlated with ALS conditions, such as FOXO1 and TGFBR2 responsible for the aberrant T cell activation, and XBP1 and SPIB accountable for excessive oxidative stress. We further identified 60 genes that distinguished ALS patients from healthy donors with an unprecedented accuracy of 93% against an independent cohort of 792 specimens. Our findings provide new molecular and cellular insights into the mechanisms of ALS onset and progression, and offer novel strategies for accurate diagnosis and potential therapeutic development. ### Competing Interest Statement Q.W. is an employee of Harcam Biomedicines who is bound by confidentiality agreements that prevents her from disclosing the competing interests in this work. All remaining authors declare no competing interest. ### Funding Statement This work was partially supported by Major Special Program Grant of Shanghai Municipality (Award Number 2017SHZDZX01), National Key Research and Development Program of China (Award Number 2021YFF1200400) and Shanghai Municipal Science and Technology Major Project (Award Number 2018SHZDZX01). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Ethics Committee of the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine (Approval #2020-060-02). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Serum heat shock protein concentrations are not associated with amyotrophic lateral sclerosis risk or survival in three European populations

Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain

Impact of histone deacetylase inhibition and arimoclomol on heat shock protein expression and disease biomarkers in primary culture models of familial ALS

The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis.

Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis

Serum Cytokines Profile Changes in Amyotrophic Lateral Sclerosis

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Single-cell transcriptional landscape of peripheral immunity and biomarkers for human sporadic amyotrophic lateral sclerosis patients

Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways

Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS

Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study

RNA Molecular Signature Profiling in PBMCs of Sporadic ALS Patients: HSP70 Overexpression Is Associated with Nuclear SOD1

Proteomic Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis

Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis

Quantification of serum TDP-43 and neurofilament light chain in patients with amyotrophic lateral sclerosis stratified by UNC13A genotype

Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein

SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study

Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes

Associations of cerebrospinal fluid profiles with severity and mortality risk of amyotrophic lateral sclerosis

Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis

Serum Uric Acid Levels Predict Mortality Risk in Male Amyotrophic Lateral Sclerosis Patients